CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an update.
CSPC Pharmaceutical Group Limited announced that its independently developed drug, SYH2068 Injection, has received approval from China’s National Medical Products Administration to conduct clinical trials. This siRNA drug targets lipoprotein(a) to treat hyperlipoproteinemia and potentially prevent atherosclerotic cardiovascular disease. Preclinical studies have shown the drug’s superior pharmacological activity and long-lasting effects, indicating promising clinical development value.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating in the pharmaceutical industry. It focuses on the development and production of innovative drugs, with a market emphasis on addressing cardiovascular and metabolic disorders.
YTD Price Performance: 8.47%
Average Trading Volume: 29,601
Technical Sentiment Signal: Buy
Current Market Cap: $9.12B
See more insights into 1093 stock on TipRanks’ Stock Analysis page.